No savings at 50? 2 FTSE 100 dividend stocks that could still help you retire in luxury

Are you approaching retirement with an empty wallet? Royston Wild explains how you can still get rich before the time you hang up your work apron.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Pensioner poverty is something we all need to get increasingly serious about. Approximately one in 20 of retired Britons is now living close to, or beyond, the breadline. I know somebody who’s close to turning 50 with hardly any savings to fall back on.

My first piece advice to them, however, was don’t panic. It’s still possible for anyone in this position to make a sizeable nest egg in the 15-or-so years between now and the State Pension age of 65. You just need to be a bit more careful with how you use your spare cash. Time isn’t on your side, after all, so picking dependable earnings generators which offer big dividends today is essential.

Medical marvel

GlaxoSmithKline (LSE: GSK) is one Footsie share I expect to deliver exceptional shareholder returns over the next decade and a half as global demand for healthcare booms.

The patent expirations on key drugs that previously crushed earnings haven’t quite been put to bed, but investors can still look forward to solid profits growth at Glaxo as sales of its new medicines take off. During the first half, for example, the rapid growth of its recently-launched Trelegy and Nucala blockbuster brands pushed revenues at its Respiratory division 16% higher to £752m.

Its product pipeline is chock-full too, with 44 new medicines in development in fast-growing areas such as infectious diseases (including HIV), oncology and respiratory for investors to look forward to. And, judging from the steady flow of positive testing updates and regulatory approvals from across the globe, it seems as if the pharma giant’s back on the path of another golden era.

One last thing to celebrate. At current prices, Glaxo trades on a forward P/E ratio of 14.8 times and carries a big 4.6% corresponding dividend yield.

Home comforts

Another dependable, big dividend payer I reckon’s a top buy today for those approaching retirement is Taylor Wimpey (LSE: TW). It currently carries a forward P/E ratio of 7.9 times and a monster dividend yield of 11.2%, making it an irresistible buy (in my opinion at least) at today’s prices.

It’s possible the fallout of the Brexit saga could have significant negative effects for the UK economy through the next decade and thereafter, a situation that could keep property price growth hemmed in. But I’m confident the housebuilders can still thrive over the long term, given the country’s chronic homes shortage.

For decades now, government has failed to get a serious handle on the problem and there’s nothing to suggest anything is about to change. Indeed, recent Whitehall pledges to build 300,000 new homes per year by the mid-202s are already in tatters, thanks in part to the miles and miles of red tape still curtailing the creation of newbuild homes. What’s more, with ultra-low interest rates now the ‘new norm’, buyer affordability is likely to remain well-supported at least through the next decade, worsening that supply/demand imbalance still further.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild owns shares of Taylor Wimpey. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »